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Abstract
Anxiety contributes to dermatological conditions and, due to the visible nature of skin
conditions, social anxiety is particularly salient to dermatology patients. Although many
dermatology outpatients report clinically significant social anxiety symptoms, there is
little understanding of social anxiety among dermatology patients. Anxiety sensitivity
(AS), or the fear of the consequences of anxiety, has been implicated in both social
anxiety and dermatological symptoms. To this end, this study aimed to further elucidate
the relation of social anxiety and AS among skin disease in two separate samples of
individuals with psychodermatological conditions. We hypothesized that AS social, but
not physical or cognitive, concerns would emerge as a unique predictor of social anxiety
symptoms after accounting for covariates. Study 1 consisted of 164 participants (Mage =
31.88; 69.5% female; 83.5% White) with active skin conditions who were recruited
through Amazon’s Mechanical Turk. Study 2 included 63 patients (Mage = 51.49; 70.7%
female; 65% White) who were recruited from an outpatient dermatology clinic. In both
samples, AS social concerns emerged as a unique factor contributing to social anxiety.
The findings suggest heightened concerns about the negative consequences related to
their visible skin condition may worsen social anxiety symptoms. Future research should
examine the efficacy of brief AS interventions that target fears of social consequences in
individuals with psychodermatological disorders.
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It’s Not Just “Skin Deep”: Social Anxiety and Anxiety Sensitivity in Adults with
Psychodermatological Disorders
Research has shown that psychological disorders are especially common in
dermatology patients, with an estimated prevalence ranging from 25% to 40% (Aktan,
Ozmen, & Sanli, 1998; Hughes, Barraclough, Hamblin, & White, 1983; Niemeier et al.,
2002; Picardi et al., 2000; Rasoulian, Ebrahimi, Zare & Taherifar, 2010; Wessely &
Lewis 1989), compared to the 17.6% rate of occurrence observed in the general
population (Kessler et al., 2012). The high rate of comorbidity of psychological and
dermatological disorders has contributed to the formation of psychodermatology for
disease classification, representing the intersection between psychiatry and dermatology.
Psychodermatological disorders represent skin conditions affected by psychological
stress, meaning that the psychological factors play a modulating role in the etiology,
course, and prognosis of these disorders (Buske-Kirschbaum & Hellhammer, 2006;
Griesemer, 1978; Jafferaney, 2007, Verhoeven et al., 2009). Psychodermatological
disorders include disorders such as acne, atopic dermatitis (eczema), psoriasis, rosacea,
urticaria (hives), vitiligo, and seborrheic dermatitis (Koo & Lebwohl, 2001).
Psychodermatological disorders have been classified into three categories:
psychophysiologic disorders, primary psychiatric disorders, and secondary psychiatric
disorders (Koo & Lee, 2003). Regarding psychophysiologic disorders, the skin disease
(e.g., acne, eczema) may be either precipitated or exacerbated by psychological factors
such as stress or anxiety, though the disease itself is not directly caused by psychological
changes. In primary psychiatric disorders, psychopathology contributes to the
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manifestation of skin symptoms. Examples include delusions of parasitosis,
trichotillomania, and skin picking from obsessive compulsive disorders. Lastly,
secondary psychiatric disorders consist of dermatologic disorders with psychiatric
symptoms, such as alopecia aerate and psoriasis. Individuals with secondary psychiatric
disorders typically experience anxiety, depression, and other emotional difficulties
because of their skin disease.
Although only formally acknowledged in recent years, the bi-directional
relationship between the mind and the skin has long been hypothesized (Sneddon, 1949).
Indeed, the two are intertwined from the very beginnings of embryological development,
with the developing brain and the skin sharing several receptors, neurotransmitters, and
hormones (Rasoulian, Ebrahimi, Zare & Taherifar 2010). The immune system, in
particular, plays a key regulatory role in the interaction between skin and psyche.
Emotional factors (e.g., stress) can precipitate changes in the immune system and
produce dermatological symptoms, such as acne breakouts and urticaria flares, by way of
histamine release and increased vasodilation (Jeremy, Holland, Roberts, Thomson &
Cunliffe, 2003; Misery, 1996; Teshima et al., 1986). This immunomodulated
inflammatory response can subsequently affect the symptomatology of dermatological
disorders by inflaming the epithelial and endothelial cells of the skin (Buske-Kirschbaum,
Gierens, Hollig & Hellhammer, 2002).
Psoriasis can be used to exemplify the interaction between skin and psychological
symptoms. For instance, one study found that 39% of psoriasis patients reported a
significant stressful event within one month prior to the first episode of the disease
(Seville, 1977). Likewise, Gaston and colleagues (1987) examined the relationship
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between stress and psoriasis prospectively over the course of twenty weeks. The results
indicated a positive correlation between the severity of psoriasis symptoms and the
ongoing experience of psychologic distress and adverse life events. Although stress and
other psychological factors have been shown to precipitate changes in the skin (Gupta,
Gupta & Watteel, 1997; Ganceviciene, Graziene, Fimmel & Zouboulis, 2009; Morren et
al., 1994; Tsukahara et al., 2003; Wygledowska-Kania, Bogdanowski & Polska, 1996),
there is also evidence that dermatology patients may be more vulnerable to psychological
syndromes. Multiple studies have indicated that psychological symptoms are common
among dermatology patients (Dalgard et al., 2015; Gascòn et al., 2012; Picardi et al.,
2000; Sheehan-Dare et al., 1990; Woodruff et al., 1997). For example, patients with
moderate to severe acne vulgaris often report elevated levels of depression, anxiety, and
suicidal ideation (Purvis, Robinson, Merry, & Watson 2006; Yazici et al., 2004).
Likewise, Ahmed and colleagues (2007) found that patients with vitiligo had significantly
higher rates of depression and anxiety than healthy controls. A population-based cohort
study conducted by Olivier and colleagues (2010) looked at anxiety, depression, and
suicidality in 149,998 psoriasis patients and 766,950 patients without psoriasis. As
expected, patients with psoriasis showed an increased risk for all three diagnoses.
Collectively, the above studies are indicative of the complex interaction between the
mind and skin, and as such, call for further examination of dermatological conditions and
co-occurring psychological factors.
Anxiety and depression are some of the most pervasive psychiatric disorders among
dermatology patients, with estimated prevalence rates of 17% and 20%, respectively
(Picardi et al., 2006). In particular, anxiety can have significant implications for skin
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diseases. For instance, anxiety disorders are associated with increases in stress responses,
and thus lead to heightened cortisol levels and inflammation (Evers, 2010). Importantly,
both high cortisol levels and inflammation can directly affect the onset, progression, and
resolution of dermatological disorders (Teshima et al., 1986; Wessely & Lewis 1989).
The estimated prevalence of anxiety disorders among dermatology patients is on the
order of 24 – 35% in outpatient clinics (Picardi et al., 2004; Woodruff, Higgens, Du
Vivier & Wesseley, 1997), although moderate to severe anxiety symptoms are discernible
in 52 – 77% of dermatology patients (Gascon et al., 2012, Rasoulian et al., 2010). Indeed,
77% of dermatology outpatients reported moderate to severe anxiety symptoms,
compared to only 26% reported by healthy controls (Rasoulian et al., 2010). Taken
together, anxiety and dermatological disorders appear to be highly comorbid.
Social anxiety disorder (SAD; previously known as social phobia) has been found
to be one of the most pervasive anxiety disorders, affecting 7.4% of the U.S population
each year (Kessler et al., 2012). According to the 5th edition of the Diagnostic and
Statistical Manual of Mental Disorders (DSM-5), the first of the diagnostic criteria for
SAD is “marked fear or anxiety about one or more social situations in which the
individual is exposed to possible scrutiny by others, including social interactions, being
observed, and performing in front of others” (American Psychiatric Association [APA],
2013). Individuals with SAD exhibit a hypersensitivity to criticism, negative evaluation,
and rejection, stemming from low self-esteem and recurrent feelings of inferiority (APA,
2013; Cox, Fleet & Stein, 2004; Stopa & Clark, 1993). Individuals with SAD often have
inaccurate perceptions of themselves, especially in social situations when they allocate
important attentional resources to monitoring their actions and the reactions of those
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around them (Rapee & Lim, 1992; Stopa & Clark, 1993). Flushing, trembling,
stammering, heart palpitations, and sweating are some of the hallmark physical indicators
of this disorder (APA, 2013). Despite the significant impairments associated with SAD,
only about half of individuals with the disorder ever seek treatment, and typically do so
after ten or more years of suffering (Wang et al., 2005).
Several negative outcomes are closely associated with SAD. First, the overall
quality of life for those suffering from SAD is often reduced (Schneider, 2006). General
impairments, which can range from performance anxiety to complete social isolation, can
result in diminished emotional and social functioning (Mennin, McLaughlin & Flanagan,
2009; Stein, Walker & Forde 1996). Individuals with SAD are much less likely to marry
than those who do not have the disorder and, for those who do marry, the decreased
occupational and interpersonal functioning can cause exceptional tension and strain on
the marriage (Salzer & Schallreuter, 2015). Work and school productivity can be
significantly impaired as well, as indicated by a threefold higher rate of unemployment
among individuals with the disorder (Wittchen & Beloch, 1996). Compared to those
without SAD, individuals with SAD report significantly more impairments in work and
school performance (Fehm, Beesdo, Jacobi & Fiedler, 2007) and are of lower
socioeconomic status than those without the disorder (Schneier et al. 1992). In addition to
the various negative outcomes of SAD, the disorder is also associated with a variety of
comorbid psychiatric conditions that can worsen disability and prognosis (Lepine &
Pelissolo, 1993). SAD is frequently comorbid with major depressive disorder and other
anxiety disorders, such as panic disorder, agoraphobia, and obsessive-compulsive
disorder (Schneier, Johnson & Hornig, 1992). Relative to skin disease, the negative
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outcomes of SAD may be particularly problematic due to the highly visible nature of
these conditions.
Dermatological disorders and SAD are highly co-morbid, with approximately 33 –
46% of dermatology outpatients reporting clinically significant social anxiety symptoms
(Bez, Yesilova, Kaya & Sir, 2011; Montgomery et al., 2016; Yarpuz, Saadet, Sanli &
Ozguven, 2008). Many dermatology patients fear that the prominence of their disease
may attract attention (or perceived attention) in social situations (Jowett & Ryan, 1985).
Further, social anxiety symptoms may worsen dermatological symptoms, further
exposing individuals to visible symptoms which might further amplify fears of scrutiny
(Dixon and Witcraft, 2018). Unfortunately, SAD symptoms tend to worsen prognosis in
dermatological patients (Salman, Kurt, Topcuoglu & Demircay, 2016; Schneider et al.,
2013).
The connection between SAD and dermatological disorders has been examined in
several studies. Salman and colleagues (2016) found that vitiligo and acne patients who
exhibited social anxiety symptoms experienced greater impairments than those without
social anxiety symptoms. Schneider and colleagues (2013) found a similar trend in
psoriasis patients, as those with social anxiety symptoms experienced significantly
greater psychological distress than those without social anxiety symptoms. Likewise,
Lessa and colleagues (2014) found that patients with both hyperhidrosis and social
anxiety symptoms experienced greater disability and a more impaired quality of life than
those with hyperhidrosis symptoms alone. Despite the fact that social anxiety symptoms
are associated with worse wellbeing of individuals with dermatological disorders, the
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empirical literature in this area is remarkably limited, and few studies have sought to
investigate the mechanisms by which they are related.
Anxiety sensitivity is thought to play a broad role in the development and
maintenance of anxiety disorders, including SAD (Naragon-Gainey, 2010; Olatunji &
Wolitzky-Taylor, 2009), and may precede the onset of anxiety disorders rather than
occurring as a consequence of the anxiety itself (Donnell & McNally, 1989, Reiss &
McNally, 1985; Taylor et al., 1992). Anxiety sensitivity (AS) is defined as the propensity
to fear the cognitive, physical, and social consequences of anxiety symptoms, such as
embarrassment, social rejection, insanity, illness, or even death (Reiss & McNally, 1980;
Taylor et al. 2007). AS is posited to be an anxiety amplifier, meaning that anxious
individuals often become alarmed about their symptoms, which subsequently intensifies
their anxiety (Taylor, Koch & McNally, 1992). For instance, an individual with SAD
might notice that s/he becomes flushed during an interview, causing his/her heart rate to
increase, which worsens flushing. Additionally, AS also plays a role in social anxiety
with co-occurring dermatological symptoms, as the association between social anxiety
and impairment due to skin disease has been shown to be mediated by AS (Dixon,
Witcraft, & Perry, 2019).
AS is comprised of three, empirically established factors: cognitive concerns,
physical concerns, and social concerns (Taylor et al., 2007). Individuals with elevated
cognitive concerns generally fear that their anxiety symptoms will lead to some form of
mental incapacitation, such as insanity. The physical concerns facet is associated with an
increased sensitivity to the physiological cues of anxiety, such as heart palpitations and
increased heart rate, with individuals interpreting the physiological symptoms as leading
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to catastrophes such as cardiac arrest or stroke. Finally, the social concerns facet is
associated with the belief that publicly observable anxiety reactions, such as flushing and
trembling, will elicit ridicule and social rejection (Taylor et al., 2007). Deacon and
Abramowitz (2006) found that the social facets of AS were particularly elevated among
individuals with SAD. Patients with SAD differed markedly from participants with other
anxiety disorders in regard to AS, with social phobics fearing anxiety-related sensations
due to the potential for negative social evaluation, not concerns about physical or
cognitive catastrophes. Given the high rates of co-morbidity between SAD and
dermatological disorders and the highly visible nature of skin disease, AS social concerns
may be an especially important vulnerability factor for individuals with
psychodermatological disorders.
Prior work suggests that the social facets of AS may play a more important
regulatory role in the development and maintenance of dermatological disorders than the
cognitive and physical concerns facets. For instance, Dixon and colleagues (2016) found
that patients with psychodermatological disorders demonstrated significantly elevated AS
when compared to patients with nonpsychodermatological disorders, but the social
concerns facets of AS had the most robust association with psychodermatological
disorders after adjusting for general anxiety symptoms. Additional research has shown
that stress is associated with skin disease quality of life among adults with active skin
disease at high, but not low, levels of AS social concerns (Dixon, Witcraft, McCowan, &
Brodell, 2018).
This preliminary research suggests that the social facets of AS are a unique
contributor to the symptoms of psychodermatological disorders, specifically SAD.

8

However, the underlying mechanisms by which the two are linked have yet to be
examined, and additional research is needed to further extrapolate the role of the different
facets of AS in dermatological patients. A more in depth understanding of the
mechanisms that connect the skin and psyche could result in more efficacious treatment
plans and potentially alleviate both psychological and dermatological symptoms. To this
end, the aim of this project is to examine associations between AS facets in relation to
social anxiety symptoms, specifically among individuals with psychodermatological
disorders in two separate samples: 1) an online sample of adults with active skin
conditions and 2) a treatment-seeking sample of dermatology patients. We hypothesized
that the AS social concerns will demonstrate a stronger association with social anxiety
symptoms as compared to the physical and cognitive concerns facets. Additionally, we
hypothesized that AS social concerns will account for more variance in social anxiety
symptoms than AS cognitive or physical concerns, after accounting for theoretically
relevant variables including age (Kessler et al., 2005), sex (Turk et al.,1998), and anxiety
(Schneier et al.,1992). We expected that these findings would be observed in the
nonclinical sample and replicated in the patient sample.
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STUDY 1
Method
Participants and Procedure
Participants were recruited through Amazon’s Mechanical Turk using
TurkPrime.com, an online crowdsourcing software that compensates “workers” for
completing tasks (Litman, Robinson, & Abberbock, 2017). To be eligible for the current
study, workers must have been located in the United States, been 18 years or older, and
completed a minimum of 100 tasks with at least an 85% approval rating. After providing
consent, eligible workers (N =1,129) completed a health screen questionnaire to
determine eligibility for the study. Individuals reporting past-year dermatological
symptoms (n = 357) were invited to participate in the second portion of the study. After
consenting to study procedures, eligible participants completed a series of questionnaires
Participants were compensated $3.50 for study procedures. The study protocol was
approved by the University of Mississippi’s Institutional Review Board.
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Data was collected from 237 participants (67.9% female; Mage = 34.18, SDage =
9.574) who consented to the study and reported current dermatological symptoms.
Participants were excluded from the current study if they did not report the presence of a
current psychodermatological condition. In accordance with the previous literature
(Dixon et al., 2016; Jafferany 2007), dermatological conditions were categorized as either
“nonpsychodermatological” and “psychodermatological.” While “psychodermatology”
refers to disorders which may be triggered or exacerbated by psychological factors (e.g.,
acne, psoriasis, atopic dermatitis), “nonpsychodermatology” refers to skin conditions
which are solely precipitated by biological factors (e.g., skin cancer, skin lesions).
Participants who reported both nonpsychodermatological and psychodermatological
conditions were classified as “psychodermatological” because it was surmised that
participants with psychodermatological disorders would report higher levels of AS
regardless of co-occurring nonpsychodermatological disorders. Additionally, primary
psychiatric disorders and secondary psychiatric disorders were excluded from the final
sample, due to the fact that these disorders tend to be psychological in origin (Koo &
Lebwohl, 2001). The following psychodermatological disorders were reported and
included in the final sample: acne, atopic dermatitis, rosacea, psoriasis, seborrheic
dermatitis, perioral dermatitis, hyperhidrosis, hives, dermatitis, ichthyosis, vitiligo,
alopecia, and factitial dermatitis. Nonpsychodermatological issues that were excluded
from the final sample included skin cancer, moles, scarring, in-grown toenails, keloids,
fungal infections, wrinkles, warts, shingles, melasmas, skin tags, birthmarks, hair loss,
lesions, rashes, trichotillomania, and body dysmorphic disorder.
Measures
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Anxiety Sensitivity Index- 3 (ASI-3). The ASI-3 (Taylor et al., 2007) includes 18
items designed to measure both the frequency and severity of the physical (“when I feel
pain in my chest, I worry that I’m going to have a heart attack”), cognitive (“when my
thoughts seem to speed up, I worry that I might be going crazy”), and social (“I worry
that other people will notice my anxiety”) facets of AS. Participants are asked to indicate
the extent to which they agree with each statement on a 5-point Likert scale, which
ranges from 0 (“very little”) to 4 (“very much”). Total scores can range from 0 to 72,
with higher scores indicating worse AS. Individuals obtaining a score of 23 or above are
classified as having clinically significant levels of AS (Allen et al., 2014). The ASI-3 has
demonstrated excellent overall internal consistency (Cronbach’s ⍺ = .93) in both clinical
and undergraduate student samples (Wheaton, Deacon, McGrath, Berman, &
Abramowitz, 2012). Additionally, the ASI-3 demonstrated good convergent and
divergent validity in that the subscales were highly correlated with similar subscales of
the original Anxiety Sensitivity Index and evidenced smaller correlations with dissimilar
subscales (Taylor et al., 2007). In the current study, the ASI-3 demonstrated excellent
internal consistency for the cognitive subscale (cog = .93) and great internal consistency
for the social and physical subscales (⍺soc= .86; phy = .89). See Appendix A.
Social Phobia Inventory (SPIN). The SPIN (Connor et al., 2000) is a 17-item,
self-report scale from 0 (“not at all”) to 4 (“extremely”). Items assess the severity of the
physiological symptoms (e.g., distressed by palpitations), avoidance (e.g., avoids
speeches), and fear (e.g., fear of talking to strangers) associated with social phobia (social
anxiety disorder). The items are summed to produce a total score, which ranges from 0 to
68, with higher scores corresponding to more severe social phobia symptoms. The
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recommended clinical cut-off of 19 discriminates between those with and without social
phobia (Connor et al., 2000). Regarding psychometric properties, the SPIN has
demonstrated excellent internal consistency in both clinical samples ( = .91) and
undergraduate samples ( = .94) (Carleton et al., 2010), and adequate test-retest
reliability (Connor et al., 2000). Lastly, the SPIN demonstrated excellent internal
consistency in the present study (Cronbach’s  = .96) See Appendix B.
Depression, Anxiety, & Stress Scales – 21 (DASS-21). The DASS-21 (Lovibond
& Lovibond, 1995) is a 21-item self-report questionnaire that assesses depression,
anxiety, and stress symptoms. Total scores range from 0 to 84, with higher scores
corresponding with more severe symptoms. Lovibond and colleagues (1995) found that
the DASS-21 successfully discriminates between depression, anxiety, and stress, despite
the fact that these syndromes are still highly correlated with one another. The anxiety
subscale (e.g., “I had feelings of shakiness”) measures physiological symptoms of anxiety
whereas the stress subscale (e.g., “I found it difficult to relax”) measures cognitive
symptoms of anxiety (Lovibond & Lovibond, 1995). The current study used only the 7item Anxiety subscale. The DASS-21-Anxiety scale has been found to have excellent
overall internal consistency (Cronbach’s  = .93) in both clinical and undergraduate
samples (Lovibond & Lovibond, 1995; Osman et al., 2012). The DASS-21-Anxiety
subscale has evidenced good convergent and discriminant validity when compared to
other validated measures of anxiety (Henry & Crawford, 2005). In the present study, the
DASS-21-Anxiety demonstrated excellent internal consistency (Cronbach’s  = .95). See
Appendix C.
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Demographics and Dermatological Information Form. Participants reported
sociodemographic characteristics, including age, sex, employment status, and education
level. In addition, participants responded to a checklist of dermatological conditions
experienced in the last four weeks (i.e., currently). See Appendix D.
Results Study 1
Participant Characteristics
Data were cleaned and examined. Per the aforementioned inclusion criteria for
psychodermatological disorders, 164 participants were included in the study and 73
participants were excluded. The overall sample was primarily female (69.5%) and was an
average age of 31.88 years (SD = 8.05). The sociodemographic characteristics in this
subsample were similar to those observed in the full sample. The majority of participants
were White (83.5%). Other ethnicities represented in the sample included Black/African
American (9.1%), Asian/Southeast Asian (6.1%), American Indian (1.2%), and 6.7%
Latin. The majority of participants had education beyond high school (87.2%) and most
were employed either part time (16.5%) or full time (56.7%).
The most frequently reported psychodermatological disorder was acne (82.3%)
followed by atopic dermatitis (32.9%) and dermatitis (15.2%; see Table 1) Additionally,
60.7% of participants reported clinically significant levels of social anxiety symptoms (M
= 28.33, SD = 18.80) and 45.1% reported clinically elevated levels of AS (M = 25.52, SD
= 16.58; see Table 1 for AS subscale scores).
Bivariate Correlations
Pearson correlations were utilized to test the hypothesis that the AS social concerns
would demonstrate a stronger association with social anxiety symptoms than the physical
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and cognitive concerns facets. As expected, AS social concerns demonstrated the highest
correlation (r = .71) with social anxiety, when compared to the physical (r = .54) and
cognitive (r = .56) concerns of AS (all p’s < 0.01). See Table 1.
Multiple Linear Regression
A multiple linear regression was computed to test the hypothesis that AS social
concerns would account for greater variance in social anxiety symptoms than AS
cognitive or physical concerns, over and above theoretically-relevant variables. In Step 1,
age, sex, and anxiety were entered as the predictors, and accounted for 34.6% of the
variance in social anxiety symptoms, F (3,160) = 29.46, p < .001. In Step 2, the physical,
cognitive, and social facets of AS were entered into the model, which accounted for an
additional 20.8% of the variance in social anxiety symptoms, ∆F (6, 157) = 24.96, p
<.001. Consistent with the hypothesis, AS social concerns, but not physical or cognitive
concerns, emerged as a unique predictor of social anxiety. See Table 3.

STUDY 2
Method
Participants and Procedure
Patients seeking outpatient dermatology care were recruited through the University
of Mississippi Medical Center (UMMC) Dermatology Clinics. Following patient checkin, UMMC Dermatology Clinic personnel introduced patients to the research study and
distributed a questionnaire packet including demographics, ASI-3, DASS-21, and SPIN
(see Study 1 for measure information). Written consent was waived by the IRB for this
study, and patients were informed in a cover letter that returning a completed measure
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packet was indicative of their consent to be a part of the study. In addition, patients were
informed that their participation (or lack thereof) would not affect their treatment, and no
compensation was provided for their participation. Interested patients returned their
anonymous questionnaire packets to clinic personnel. The study protocol was approved
by the University of Mississippi’s Institutional Review Board.
Inclusion and Exclusion Criteria. To be eligible for the study, the patients had to
be 18 years or older and English speaking. This study used the same criteria as Study 1 to
identify between participants with psychodermatological disorders. That is, participants
who reported non-psychodermatological disorders, such as skin cancer, were excluded
from this study.
Measures
Anxiety Sensitivity Index- 3 (ASI-3). See study 1 for the psychometric properties
of ASI-3. In Study 2, the internal consistency ranged from great to excellent for all three
subscales (⍺soc= .86; cog = .93; phy = .89).
Social Phobia Inventory (SPIN). See Study 1 for the psychometric properties of
SPIN. In Study 2, the internal consistency was adequate ( = .76).
Depression, Anxiety, & Stress Scales – 21 (DASS-21). See Study 1 for the
psychometric properties of the DASS-21. In Study 2, the internal consistency was great
( = .89).
Demographics Form. This form was utilized to obtain general medical and
demographic information. The questionnaire included items assessing age, sex,
marital/relationship status, ethnicity, education, total family/household income, and
employment status. In addition, patients identified their current dermatological issues or
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diagnoses by circling common disorders and/or responding to a free-response item. See
Appendix E.
Results
Participant Characteristics
The data were cleaned and participants who did not complete measures pertinent to
the current study were excluded from analyses. Using the previously described inclusion
criteria, 60 participants were excluded from the current study and the final sample was
comprised of 63 participants with psychodermatology disorders. The final sample was
primarily female (81%), and was on average 47.94 years old (SD = 16.05). Participants
identified as White (58.7%), Black/African American (39.7%), and Native American
(1.6%). Additionally, most individuals had education beyond high school (73.0%), were
employed (52.4%), and married (50.8%). The most common psychodermatological
disorder was acne (31.8%), followed by atopic dermatitis (30.1%) and psoriasis (27%).
Overall, 27.2% of patients reported social anxiety levels of clinical significance (M =
15.65, SD = 14.69) and 35.2 % of participants reported clinically significant levels of AS
(M = 21.03, SD = 16.76; see Table 1 for AS subscale scores).
Bivariate Correlations
Pearson correlations revealed that that among psychodermatology patients, the
correlation between the social facets of AS social anxiety symptoms was large (r = .75)
whereas medium-sized correlations were observed between social anxiety symptoms and
AS physical (r = .49) and cognitive facets (r = .56; all ps <.01). See Table 1.
Multiple Linear Regression
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In Step 1, age, sex, and anxiety were entered as the predictors, and accounted for
34.1% of the variance in social anxiety symptoms F (3,55) = 10.004, p < .001. In Step 2,
the physical, cognitive, and social facets of AS were entered into the model, which
accounted for an additional 26.6% of the variance in social anxiety symptoms, ∆F (3, 55)
= 12.421, p <.001. Supporting the hypothesis, AS social concerns, but not physical or
cognitive concerns, emerged as a unique predictor of social anxiety. See Table 4.

Discussion
The current study examined the physical, cognitive, and social facets of AS in
relation to social anxiety symptoms in two samples of adults with psychodermatological
disorders. In both samples, AS social concerns emerged as a unique factor contributing to
social anxiety symptoms, above the theoretically-relevant covariates of age, sex, and trait
anxiety. These findings suggest heightened concerns about the negative social
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consequences related to their visible skin condition may exacerbate social anxiety
symptoms among individuals with psychodermatological disorders.
Participants in both studies demonstrated elevated levels of social anxiety, with
60.7% and 27.2% of individuals reporting clinically significant levels of social anxiety in
the online and patient samples, respectively. These results are consistent with those of
prior studies which have shown high rates of comorbidity between SAD and
dermatological disorders (Bez, Yesilova, Kaya & Sir, 2011; Montgomery et al., 2016;
Yarpuz, Saadet, Sanli & Ozguven, 2008). Interestingly, participants in Study 1
demonstrated significantly elevated social phobia levels when compared to the
participants in Study 2. This disparity could be attributed to a variety of factors, such as
differences in demographics and sample size. For instance, the sample in Study 1 (N =
164) was larger than that of Study 2 (N = 62), and a larger sample size minimizes the
effects of statistical outliers. Further, participants in Study 1 were on average 16 years
younger than those in Study 2, which is consistent with previous research which finds
that social anxiety is more prevalent among younger samples (Cairney et al., 2007; Flint
et al., 2010; Kessler et al., 2005; Regier et al., 1988). Anxiety disorders, such as SAD,
have a peak age of onset in early adulthood and their incidence and prevalence decline
later in life (Kessler et al., 2005), and individuals may become more adept at managing
their social anxiety with age (Henderson, Form, Korten & Jacomb, 1998). Individuals
who report highly visible dermatological symptoms tend to report significantly elevated
levels of social anxiety, which could explain the comparably high levels of social anxiety
in Study 1 (Montgomery, Norman, Messenger & Thompson, 2016; Salman, Kurt,
Topcuoglu & Demicray, 2016). In Study 1, the majority of participants reported acne as

19

their chief dermatological complaint (82.3%), whereas participants in Study 2 reported
notably lower rates of acne (31.8%), and a higher frequency of psoriasis (Study 1: 8.5%
vs. Study 2: 27%). Research suggests that SAD may be prevalent in as many as 45.7% of
acne patients (Bez, Yesilova, Kaya & Sir, 2011), though SAD prevalence rates appear to
be as low as 4% among individuals with disorders such as psoriasis (Golpour et al.,
2012). Acne symptoms are typically localized to highly visible areas of the body (e.g.,
face, upper back, chest), whereas psoriasis and eczema may present to more concealable
areas of the body (e.g., Shalita, 2004).
Consistent with expectations, although the three facets of AS were positively
correlated with social anxiety symptoms, the social concerns facets demonstrated the
strongest association with social anxiety symptoms in both samples. These findings
support the premise that individuals with psychodermatological disorders may experience
elevated concerns about the social consequences of physiological arousal due to the
visible nature of skin disease (e.g., sweating). Further, as these samples, on average,
experienced elevated levels of social anxiety symptoms, it stands to reason that they may
also experience concerns about the physical and cognitive consequences related to
anxiety.
As hypothesized, the social facets of AS emerged as a unique predictor of social
anxiety symptoms in both psychodermatological samples. These results are consistent
studies implicating the social facets of AS in the etiology and maintenance of SAD
(Olthius, Watt & Stewart, 2014). Although previous literature has established age
(Kessler et al., 2005), gender (Asher & Aderka; 2018), and anxiety (Schneier et al.,1992)
as significant risk factors for SAD, the current study suggests that the social facets of AS
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play a more salient role in social anxiety among psychodermatological conditions. Adults
with skin disease may fear that their anxiety-related symptoms and the visibility of their
dermatological symptoms will result in negative consequences, such as ridicule, social
rejection, negative evaluation, and worsened dermatological symptomatology (i.e., acne
breakout or psoriasis flare). These fears may result in greater distress and psychosocial
impairment, which could further exacerbate skin symptoms.
Although this study replicated and extended current knowledge of the
psychodermatology literature, several limitations warrant consideration. First, the
methodology of the first study relied on an online crowdsourcing platform. Although
attention check questions were used to exclude careless responders and to improve
validity (Meade & Craig, 2012), participants could have answered questionnaires
dishonestly or carelessly, and dermatological symptoms were not verified by a clinician.
These limitations were partially addressed in Study 2, which used an in-person sample of
patients presenting to a dermatology clinic and paper-pencil questionnaires. Second, the
cross-sectional design of both studies precludes temporal or causal associations.
Longitudinal studies are needed to better understand the development of
psychodermatological disorders, social anxiety symptoms, and the social facets of AS
over time and to identify additional risk factors. Third, social anxiety symptoms were
assessed via self-report, rather than clinical interview. Future studies should seek to
replicate the findings of Study 1 and Study 2 in a clinical sample of individuals diagnosed
with SAD. Additionally, both samples lacked gender diversity, as the majority of
participants were female (Study 1 = 69.5%; Study 2 = 81.0%). Although the sample
limits the generalizability of the findings, females account for approximately 60% of
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dermatology visits (Stern 2004) and have higher lifetime prevalence rates of SAD
compared to men (Weinstock, 1999; Xu et al., 2012). Therefore, the results may represent
a majority of patients presenting to dermatology clinics with social concerns. Next, high
correlations between AS facets in Study 2 indicates potential for multicollinearity, such
that one of the facets may be suppressed in accounting for variance in the outcome.
Lastly, dermatological disorders in Study 1 and Study 2 were dichotomized as either
psychodermatological or nonpsychodermatological and not examined on an individual
basis. Subsequent research should target specific psychodermatological and
nonpsychodermatological disorders to look for variance, or lack thereof, in social anxiety
symptoms and social AS among individuals with different disorders.
Psychological interventions appear to be useful adjuncts to conventional
dermatological treatments for individuals with psychodermatological disorders, and
improving the specificity of such treatments by targeting the social facets of AS could
potentially streamline intervention processes and maximize effectiveness (HedmanLagerlof, Bergman, Lindefors & Bradley, 2018; Shenefelt, 2000; Smits, Berry, Tart &
Powers, 2008; Woodruff, Higgens, Du Vivier & Wessely, 1997). Interventions such as
cognitive-behavioral therapy, which work by altering the dysfunctional thought patterns
or actions that are associated with anxiety symptoms, have been shown to effectively
reduce AS (Capron & Schmidt, 2016; Kneough & Schmidt, 2012; Olthuis, Watt,
MacKinnon & Stewart, 2014). In the future, dermatologists and other clinicians may use
assessments of AS social concerns to screen for at risk individuals and provide brief AS
interventions targeting social concerns related to their skin and anxiety symptoms.
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Clinicians could also refer at-risk patients to psychology specialists or therapists for
further psychological evaluation and treatment.
In summary, psychodermatology is relatively new area of research, and the
literature within this discipline is remarkably limited. This study is one of the few of its
kind to examine SAD among individuals with psychodermatological disorders, and the
findings regarding the social facets of AS have further elucidated the mechanisms by
which the mind and skin are related. Moreover, this study provides a replication,
demonstrating that the social facets of AS appear to be a unique contributor to social
anxiety symptoms in both clinical and nonclinical samples.
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Table 1. Psychodermatological disorders
Study 1 (N = 164)
% (n)
Acne
82.3 (135)
Eczema (Atopic Dermatitis)
32.9 (53)
Psoriasis
8.5 (14)
Dermatitis
15.2 (25)
Seborrheic Dermatitis
11.0 (18)
Factitial Dermatitis
1.8 (3)
Rosacea
6.7 (11)
Urticaria (hives)
3.0 (5)
Alopecia Areata
1.2 (2)
Vitiligo
0.6 (1)
Ichthyosis
0.6 (1)
Prurigo Nodularis
0.0
Hyperhidrosis
3.0 (5)

38

Study 2 (N = 63)
% (n)
31.8 (20)
30.1(19)
27 (17)
3.2 (2)
0.0
0.0
6.4 (4)
0.0
4.8 (3)
1.6 (1)
0.0
1.6 (1)
1.6 (1)

Table 2. Means, Standard Deviations, and Correlations between Study Variables
Study 1
Study 2
1.
2.
3.
4.
5.
M (SD)
M (SD)
1. Anxiety
10.69 (9.82) 7.98 (10.76)
.57** .52** .66** .59**
2. Social Anxiety 28.32 (7.88) 15.65 (14.69) .59**
.48** .56** .747**
3. AS Physical
7.88 (6.42)
7.63 (6.28)
.65**
.54**
.79** .71**
4. AS Cognitive
5.92 (6.57)
5.48 (6.01)
.65**
.55** .65**
.74**
5. AS Social
11.71 (6.30)
7.98 (6.19)
.567** .71** .61** .57**
Note. M = mean; SD = standard deviation. Anxiety= DASS-21 Anxiety; Social Anxiety=
Social Phobia Inventory total; AS Physical, AS Cognitive & AS Social = three subscales of the
ASI-3. Values below the diagonal of the correlation matrix are from the MTurk sample; values
above the diagonal are from the patient sample.
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Table 3. Multiple linear regression of anxiety sensitivity facets in social anxiety
symptoms among MTurk workers (N = 164)
B
SE(B)
p
R2
Step 1
.356
<.001
Age
-.074
.153
.628
Sex
-1.785
2.375
.453
Anxiety
1.129
.125
<.001
Step 2
.208
<001
Age
-.142
.128
.270
Sex
.020
1.993
.992
Anxiety
.396
.152
.010
AS Physical
.048
.232
.838
AS Cognitive
.327
.221
.140
AS Social
1.519
.212
<.001
Note. AS = Anxiety sensitivity; anxiety= DASS-21 Anxiety; social anxiety = Social
Phobia Inventory total; AS Physical, AS Cognitive & AS Social = three subscales of the
ASI-3.
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Table 4. Multiple linear regression of anxiety sensitivity facets in social anxiety
symptoms among psychodermatology patients (N = 63)
B
SE(B)
p
R2
Step 1
.341
<.001
Age
0.062
-.068
.548
Sex
.580
.016
.889
Anxiety
.777
.571
<.001
Step 2
.266
<001
Age
.023
.083
.781
Sex
-1.341
3.312
.687
Anxiety
.316
.161
.054
AS Physical
-.407
.339
.325
AS Cognitive
-.031
.401
.939
AS Social
1.763
.323
<.001
Note. AS = Anxiety sensitivity; anxiety= DASS-21 Anxiety; social anxiety = Social
Phobia Inventory total; AS Physical, AS Cognitive & AS Social = three subscales of the
ASI-3.
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Appendix A
Anxiety Sensitivity Index-3
Please circle the number that best corresponds to how much you agree with each item. If
any items concern something that you have never experienced (e.g., fainting in public)
answer on the basis of how you think you might feel if you had such an experience.
Otherwise, answer all items on the basis of your own experience. Be careful to circle only
one number for each item and please answer all items.
Very
A
Very
Little little Some Much much
1. It is important for me not to appear
nervous.

0

1

2

3

4

2. When I cannot keep my mind on a task,
I worry that I might be going crazy.

0

1

2

3

4

3. It scares me when my heart beats
rapidly.
4. When my stomach is upset, I worry that
I might be seriously ill.

0

1

2

3

4

0

1

2

3

4

5. It scares me when I am unable to keep
my mind on a task.

0

1

2

3

4

6. When I tremble in the presence of
others, I fear what people might think of
me.
7. When my chest feels tight, I get scared
that I won’t be able to breathe properly.

0

1

2

3

4

0

1

2

3

4

8. When I feel pain in my chest, I worry
that I am going to have a heart attack.

0

1

2

3

4

9. I worry that other people will notice my
anxiety.

0

1

2

3

4
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10. When I feel “spacey” or spaced out I
worry that I may be mentally ill.

0

1

2

3

4

11. It scares me when I blush in front of
people.
12. When I notice my heart skipping a beat,
I worry that there is something seriously
wrong with me.
13. When I begin to sweat in a social
situation, I fear people will think
negatively of me.
14. When my thoughts seem to speed up, I
worry that I might be going crazy.

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

15. When my throat feels tight, I worry that
I could choke to death.

0

1

2

3

4

16. When I have trouble thinking clearly, I
worry that there is something wrong
with me.
17. I think it would be horrible for me to
faint in public.

0

1

2

3

4

0

1

2

3

4

18. When my mind goes blank, I worry
there is something terribly wrong with
me.

0

1

2

3

4
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Appendix B
Social Phobia Inventory (SPIN)
Directions: Please circle the number that best corresponds to how much the statement
applied to you over the past week. There are no right or wrong answers. Do not spend too
much time on any one statement.
A
Not
little Some
Very
Extremely
at all
what
bit
Much
1. I am afraid of people in authority.
2. I am bothered by blushing in front of
people.
3. Parties and social events scare me.
4. I avoid talking to people I don’t
know.
5. Being criticized scares me a lot.
6. I avoid doing things or speaking to
people for fear of embarrassment.
7. Sweating in front of people causes
me distress.
8. I avoid going to parties.
9. I avoid activities in which I am the
center of attention.
10. Talking to strangers scares me.
11. I avoid having to give speeches.
12. I would do anything to avoid being
criticized.
13. Heart palpitations bother me when I
am around people.
14. I am afraid of doing things when
people might be watching.
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0

1

2

3

4
4

0

1

2

3

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0
0

1
1

2
2

3
3

4
4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

15. Being embarrassed or looking stupid
are among my worst fears.
16. I avoid speaking to anyone in
authority.
17. Trembling or shaking in front of
others is distressing to me.

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

Appendix C
DASS-21
Anxiety Subscale
Choose the number which indicates how much the statement applied to you over the past
week.
0 = Did not apply to me at all
1 = Applied to me to some degree, or some of the time
2 = Applied to me to a considerable degree, or a good part of the time
3 = Applied to me very much, or most of the time
________

1. I was aware of dryness in my mouth.

________

2. I experienced breathing difficulty (e.g., excessively rapid breathing,
breathlessness in the absence of physical exertion).

________

3. I experienced trembling (e.g., in the hands).

________
of

4. I was worried about situations in which I might panic and make a fool
myself.

________

5. I felt I was close to panic.

________
(e.g.,

6. I was aware of the action of my heart in the absence of physical exertion
sense of heart rate increase, heart missing a beat).

________

7. I felt scared without any good reason.
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Appendix D
Medical Screening Questions

1. In the last 12 months, have you experienced insomnia, difficulties falling
asleep, or other sleeping problems (example: frequent waking)?
2. In the last 12 months, have you experienced, had difficulties with, or seen a
medical provider for a dermatology condition or for symptoms related to skin
problems (examples: rosacea, psoriasis, acne, eczema)?
3. In the last 12 months, have you used prescription drugs (e.g., pain pills,
Xanax, stimulants) for non-medical purposes (examples: to get high, feel
better)?
4. In the last 12 months, have you experienced perfect health every single day,
all day? (examples: complete absence of: illness, ailments,
headaches/stomachaches)

☐
☐No
Yes

5. For women, are you currently pregnant or did you give birth to a
child in the last 12 months?

☐
☐No
Yes
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☐ N/A

☐
☐No
Yes
☐
☐No
Yes
☐
☐No
Yes

Appendix E
Demographics Form
Age: __________
Sex: ___Female

___ Male

Marital/Relationship Status:
_____ (1) Single (never married, living alone, divorced, widowed, etc.)
_____ (2) Living with a partner as if married
_____ (3) Married BUT separated
_____ (4) Married
Ethnicity / Race:
___ (1) White/Caucasian
___ (2) Black/African American
___ (3) Asian/Southeast Asian

___ (4) Hispanic /Latino
___ (5) Native American

Education (the highest grade or degree you have completed):
___ (1) None
___ (2) 1st to 8th Grade
School
___ (3) Some High School
___ (4) High School Graduate
School
___ (5) G.E.D.
Degree

___ (6) Some College
___ (7) Technical or Business
___ (8) College Graduate
___ (9) Some Graduate
___ (10) Graduate or Professional
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Total Family/Household Income (Please check one):
___$0 - 9,999
___$10,000 – 19,999
___$20,000 – 29,999
___$30,000 – 39,999

___$40,000 – 49,999
___$50,000 – 59,999
___$60,000 – 69,999
___$70,000 – 79,999

___$80,000 – 89,999
___$90,000 – 99,999
___$100,000 or more

Employment Status:
___ (1) unemployed

___ (5) home-maker

___ (2) employed part-time (working 1-30 hours a week)
time student
___ (3) employed full-time (working more than 30 hours a week)
___ (4) full-time student

___ (6) part___ (7) retired

What are your current dermatological diagnoses? If unsure or no diagnosis, what
issues, or concerns are you experiencing? (Please circle all that apply and/or describe
current concerns)
________________________________________________________________________
__________________
________________________________________________________________________
__________________
Acne

Birthmarks
Hidradenitis

Eczema

Herpes

Hyperhidrosis (excessive sweating) Melasma
Rosacea

Psoriasis

Scars

Vitiligo

Skin Cancer
Wrinkles

Sun Damage
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